Literature DB >> 27238199

Successful treatment of refractory lupus nephritis by the sequential use of rituximab and belimumab.

Federico Simonetta1, Danièle Allali2, Pascale Roux-Lombard2, Carlo Chizzolini3.   

Abstract

Entities:  

Keywords:  BAFF; Belimumab; Lupus nephritis; Rituximab; SLE

Mesh：

Substances：

Year:  2016        PMID： 27238199     DOI： 10.1016/j.jbspin.2016.01.008

Source DB:  PubMed          Journal:  Joint Bone Spine        ISSN： 1297-319X            Impact factor:   4.929


× No keyword cloud information.
  14 in total

Review 1.  Inflammatory Joint Disorders and Neutrophilic Dermatoses: a Comprehensive Review.

Authors:  Massimo Cugno; Roberta Gualtierotti; Pier Luigi Meroni; Angelo Valerio Marzano
Journal:  Clin Rev Allergy Immunol       Date:  2018-04       Impact factor: 8.667

Review 2.  B Cell-Based Treatments in SLE: Past Experience and Current Directions.

Authors:  Stamatis-Nick C Liossis; Chrysanthi Staveri
Journal:  Curr Rheumatol Rep       Date:  2017-11-04       Impact factor: 4.592

Review 3.  New Trials in Lupus and where Are we Going.

Authors:  Aikaterini Thanou; Joan T Merrill
Journal:  Curr Rheumatol Rep       Date:  2018-05-03       Impact factor: 4.592

Review 4.  New therapeutic strategies in systemic lupus erythematosus management.

Authors:  Mariele Gatto; Margherita Zen; Luca Iaccarino; Andrea Doria
Journal:  Nat Rev Rheumatol       Date:  2019-01       Impact factor: 20.543

Review 5.  Belimumab and low-doses of mycophenolate mofetil as induction therapy of class IV lupus nephritis: case series and literature review.

Authors:  Domenico Paolo Emanuele Margiotta; Fabio Basta; Veronica Batani; Antonella Afeltra
Journal:  BMC Nephrol       Date:  2018-03-07       Impact factor: 2.388

Review 6.  Current perspective on rituximab in rheumatic diseases.

Authors:  Tommaso Schioppo; Francesca Ingegnoli
Journal:  Drug Des Devel Ther       Date:  2017-10-03       Impact factor: 4.162

Review 7.  Novel Treatments in Lupus.

Authors:  Milena Vukelic; Yi Li; Vasileios C Kyttaris
Journal:  Front Immunol       Date:  2018-11-16       Impact factor: 7.561

8.  Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults with systemic lupus erythematosus (SLE): BLISS-BELIEVE study protocol.

Authors:  Y K Onno Teng; Ian N Bruce; Betty Diamond; Richard A Furie; Ronald F van Vollenhoven; David Gordon; James Groark; Robert B Henderson; Mary Oldham; Paul P Tak
Journal:  BMJ Open       Date:  2019-03-20       Impact factor: 2.692

9.  Efficacy of Belimumab for active lupus nephritis in a young Hispanic woman intolerant to standard treatment: a case report.

Authors:  Francesco Fontana; Gaetano Alfano; Marco Leonelli; Caterina Cerami; Giulia Ligabue; Amelia Spinella; Giorgia Citriniti; Carlo Umberto Manzini; Clodoveo Ferri; Gianni Cappelli
Journal:  BMC Nephrol       Date:  2018-10-20       Impact factor: 2.388

10.  Efficacy and Safety of Belimumab and Azathioprine for Maintenance of Remission in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Controlled Study.

Authors:  David Jayne; Daniel Blockmans; Raashid Luqmani; Sergey Moiseev; Beulah Ji; Yulia Green; Leanne Hall; David Roth; Robert B Henderson; Peter A Merkel
Journal:  Arthritis Rheumatol       Date:  2019-04-16       Impact factor: 10.995
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.